WCLC Closing Plenary Explored Overcoming Barriers to Patient Advocacy Worldwide
Haleigh BehrmanGlobal leaders in patient advocacy assembled during the 2024 World Conference on Lung Cancer to shed light on ongoing initiatives. Read more
Outdoor air pollution is classified as a group 1 carcinogen and significantly impacts lung cancer risk in individuals—especially among females—including those with no smoking history. Recent data indicate that fine particulate matter measuring 2.5 microns or smaller (PM2.5) may be linked to genomic alterations.
“We found significant associations between EGFR status and the characteristics of lung cancer patients,” said Yixian Crystal Chen, PhD, a researcher at the British Columbia Cancer Research Institute in Vancouver, Canada. “One of the most concerning parts of air pollution is PM2.5. These small particles can go deep into the lungs and even get into the bloodstream, posing serious health risks for people, even those who do not smoke.”
Dr. Chen presented the data during a session on understanding lung cancer risk factors during the 2024 World Conference on Lung Cancer in San Diego.
Researchers collaborated with patients with no smoking history who were diagnosed with lung cancer at BC Cancer Center, Vancouver, to establish individual residential histories and assess PM2.5 exposures using detailed satellite and ground measurements, as well as chemical transport models from 1996 onward. The genomic variables examined included EGFR and ALK mutations. Of the patients, 56% tested positive for EGFR and/or ALK mutations.
EGFR- and ALK-positive patients were more likely to be Asian, born outside Canada, diagnosed at stage IV, and have adenocarcinoma, Dr. Chen said. The association between PM2.5 and EGFR-positive status was stronger in females (p < 0.001) than in males (p = 0.007).
In a subgroup of 188 female lung cancer patients, those with genomic mutations exhibited higher exposure to PM2.5 in the year, 3 years, and 5 years before diagnosis compared to patients without genomic mutations. Dr. Chen said that this association was not observed in males with no smoking history.
Exposure to higher levels of PM2.5 was associated with an odds ratio of approximately 1.3 for EGFR mutations (p = 0.024) and 1.2 for both EGFR and ALK mutations (p = 0.025).
Dr. Chen said the odds ratios highlight a strong link between PM2.5 exposure and subsequent oncogenic mutations. Short-term exposure to PM2.5 may play a crucial role in the development of lung cancer in patients with no smoking history, particularly through the activation of EGFR mutations.
There was a similar numerical trend for cumulative 10-year exposure to PM2.5, with levels of 78.6 μg/m3 for EGFR-positive and ALK-positive patients compared to 69 μg/m3 for those without EGFR or ALK mutations. However, the association was not statistically significant (p = 0.219).
“Our study suggests that short-term cumulative exposure may impact genomic operations in female lung cancer patients who have never smoked,” Dr. Chen said. “The model warrants the study of the prevalence of adenocarcinoma among patients with genomic alterations and also highlights the importance of understanding these specific changes. We need to confirm these results with larger cohorts and people from different geographic regions. This research opens important avenues for understanding the link between air pollution and lung cancer.”
Study Evaluating Tusamitamab Ravtansine in Patients with Non-Squamous NSCLC is Discontinued
Fred GebhartDr. Benjamin Besse recently discussed detailed findings from the now discontinued CARMEN-LC03 trial. Read more
LUMINOSITY Subgroup Analysis Shows Similar Results for Asian Patients Compared to Global Population
Fred GebhartDr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression. Read more
TROPION-Lung01 Demonstrates Improvement in PFS; OS Improvement Fails to Reach Statistical Significance
Fred GebhartDr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort. Read more
Climate Change, Pollution, War, and More Increasing Risk, Impacting Management of Lung Cancer Worldwide
Haleigh BehrmanDr. Leticia Nogueira and other experts explored non-tobacco factors that are playing a role in our evolving knowledge during a WCLC 24 plenary session. Read more
Artificial Intelligence-Powered Tools May Help Develop Predictive Biomarkers
Fred GebhartDr. Kenneth O’Byrne says research shows novel method for analyzing tissue samples may help predict immunotherapy response. Read more
Interim Analysis Shows IDeate-Lung01 Study Met Primary Endpoint
Fred GebhartDr. Charles Rudin says early data look promising for I-DXd in patients with ES-SCLC. Read more
Hands-On Genomics Workshop Enables Participants to Integrate Genomic Testing Into Patient Care
Krithika Subramanian, PhDDrs. Ramaswamy Govindan, Richard Haspel, and Aparna Sharma took the audience on a guided tour of pragmatic lung cancer genomics. Read more
Save the Date: Planning Begins for the 2025 World Conference on Lung Cancer
Haleigh BehrmanDrs. Isabelle Opitz, Umberto Malapelle, Noemi Reguart, and Jarushka Naidoo will co-chair the event, which will return to Barcelona next September. Read more